Replies to post #47 on Immix Biopharma Inc (IMMX)

[Milo1]

It's the other applications that are in process for this drug that are relevant, and the PRV which will likely be awarded which has a cash value of $150-$300M

GL with that short position though..lol

[Milo1]

It's the "Rare Pediatric disease" designation which is key here. By getting this they will be awarded a PRV worth up to $300M which will fund all their research for other applications for this same drug, and others in their pipeline.

[Milo1]

If you have patience IMMX could easily reach $100-$200/share within a couple years. Use that multiple against how much you make day flipping and see if it might be worth your while.

[Milo1]

You are incorrect here btw. 20,000 cases per year in the US. Other applications far more.